Dindevan (phenindione) is a medication utilized in therapeutic regimens to manage conditions associated with blood clot formation.

Quick Facts: Therapeutic Domains

• Support for managing venous thromboembolism: Used in the treatment and prevention of blood clots, particularly in deep veins (Deep Vein Thrombosis).
• Assistance in pulmonary embolism: Employed to address the presence or potential formation of blood clots that travel to the lungs.
• Reduction of risk for systemic embolism: May be prescribed for patients with pre-existing conditions, such as certain heart rhythm abnormalities, to help lower the chance of clot-related complications.
• Prophylaxis following heart valve procedures: Used to mitigate the risk of clot formation after the insertion of prosthetic heart valves.

This medication is part of a comprehensive strategy to maintain blood flow and is administered to support individuals requiring long-term anticoagulation. Treatment aims to prevent the extension of existing clots and reduce the risk of secondary thromboembolic events, which may include stroke.

Eligibility Profile for Dindevan (Phenindione)

Classification	Population/Condition
Absolute Contraindication	Severe renal or hepatic disease, bacterial endocarditis, uncontrolled hypertension, and actual or potential haemorrhagic conditions, including haemorrhagic stroke.
Absolute Contraindication	Hypersensitivity to Phenindione or excipients.
Life-Stage Prohibition	Pregnant women, due to teratogenicity and foetal haemorrhage risk. Women who are breastfeeding, as the drug is distributed into breast milk. Use is also prohibited within 48 hours postpartum.
Standard Use Population	Adults are the primary eligible population for whom posology is defined.
Restricted/Conditional Use	Elderly patients require a mandatory reduction of dosage and more frequent INR monitoring due to increased risk of bleeding.
Restricted/Conditional Use	Patients with deficient renal function (non-severe), liver disease, active peptic ulceration, or acute illnesses require special caution and dose consideration.
Use Not Established	The regulatory documentation does not define a specific profile or regimen for the pediatric population (children and adolescents).

Interactions with other medicines and products

Dindevan (phenindione) has a narrow therapeutic index and interacts with a wide variety of medicines, supplements, and foods, primarily by altering the risk of bleeding or by modifying drug exposure.

Contraindicated and High-Risk Combinations

Co-administration is contraindicated with certain substances, including fibrinolytic drugs (e.g., streptokinase, alteplase), due to a significantly increased risk of hemorrhage. Caution is mandatory when combining Dindevan with any other medicine that affects hemostasis or platelet function, such as non-steroidal anti-inflammatory drugs (NSAIDs), anti-platelet agents, or other anticoagulants.

Exposure Modification

Many medications can either potentiate (increase activity) or antagonize (decrease activity) the effects of Dindevan:

• Potentiation/Increased Effect: Observed with medicines such as cimetidine, allopurinol, amiodarone, metronidazole, and broad-spectrum antibiotics.
• Antagonism/Decreased Effect: Occurs with enzyme-inducing agents like carbamazepine, rifampicin, and phenytoin, as well as with cholestyramine and sucralfate.

Food, Supplements, and Other Substances

Consumption of large amounts of alcohol or Cranberry juice must be avoided. Foods high in Vitamin K (e.g., green leafy vegetables, broccoli) may antagonize Dindevan’s effect. Herbal products and food supplements, particularly those affecting coagulation or hepatic enzymes (e.g., St. John's Wort), should be avoided unless discussed with a healthcare professional.

Procedural and Population Notes

For patients initiating therapy, it is noted that concomitant heparin therapy must be discontinued at least six hours prior to the first INR control test. In elderly patients and those with deficient renal function, the effects of Dindevan may be exaggerated, potentially requiring careful consideration of interacting substances.

Inhibition of Vitamin K Recycling

This mechanism involves the targeted molecular inhibition of the liver enzyme Vitamin K Epoxide Reductase (VKOR). By blocking this essential recycling process, Phenindione starves the hepatic cells of the necessary active Vitamin KH2 cofactor, resulting in the downstream synthesis of non-functional coagulation factors.

---

Impairment of Coagulation Factor Activation

The resulting deficiency of active Vitamin KH2 prevents the final activation step (gamma-carboxylation) of key pro-clotting factors (II, VII, IX, and X) and natural anticoagulants (Proteins C and S). This molecular impairment causes the release of non-functional proteins (PIVKA) into the circulation, which cannot properly participate in the coagulation cascade.

---

Systemic Reduction of Blood Coagulability

The widespread functional deficit of active coagulation factors throughout the bloodstream leads to a systemic prolongation of clotting time. This resulting physiological change is the primary outcome of the drug's mechanism, and the final physiological consequence is a decrease in the intrinsic capacity of the blood to form thrombi. The effect is delayed, as it relies entirely on the natural clearance rate of pre-existing, active factors.

Administration Guidelines for Dindevan (Phenindione)

Dindevan is administered via the oral route as a tablet, available in 10 mg and 25 mg strengths. The tablets must be swallowed whole with water, and the score line on the 25 mg tablet is not intended for tablet division. Dosing is generally structured in two phases: an initial loading period followed by a long-term maintenance regimen.

---

Dosing and Frequency

Treatment begins with a loading dose of 200 mg on the first day, followed by 100 mg on the second day. From the third day onward, the patient transitions to a maintenance dose, which typically ranges from 50 mg to 150 mg daily. The medication is taken once daily, and the dose is typically taken at the same time each day.

---

Procedural Use and Adjustments

The maintenance dose is not fixed; it is adjusted based on the results of routine coagulation tests, specifically the International Normalised Ratio (INR). This frequent laboratory monitoring is required to establish the correct ongoing dose and continues at longer intervals once the INR is stable. If switching from concomitant heparin therapy, the heparin is discontinued at least six hours prior to the first INR control test.

Special Population Rules

A reduction of dosage may be required for older adults and for individuals with deficient renal function. Dindevan is not suitable for use in children, defining its application to the adult population.

---

This structured protocol, moving from an initiation phase to a monitored, lab-dependent daily intake, constitutes the clinical framework for the use of the medicine.

Research Evidence / Overview of studies for Dindevan

The research behind Dindevan (Phenindione) is connected to a larger family of medicines known as Vitamin K Antagonists (VKAs). While Phenindione itself was studied historically, its current standing relies primarily on the extensive research conducted on the VKA class as a whole, which explores the use of these medicines in the context of blood clot risks. This overview describes the research structure and the findings reported, without giving any individual advice or predictions.

---

Evidence for Prevention and Treatment of Venous Thromboembolism (VTE)

Research was studied for outcomes reflecting episodic or acute changes in a deep vein clot or a clot in the lung, conditions known collectively as VTE. Trials and systematic reviews research examined adult populations with confirmed DVT or PE. The evidence was studied for outcomes related to systemic or functional imbalance. The body of evidence for Phenindione was derived from historical controlled studies, which is often supplemented by research on other VKAs.

It is not yet clear whether research has explored direct comparisons of Phenindione to the newest alternatives. Long-term effects are not fully established specifically for Phenindione in modern clinical settings.

---

Evidence for Prevention of Systemic Embolism

Research has explored the use of VKA medicines in the context of clot-related complications arising from the heart, such as stroke, especially in individuals with conditions like Atrial Fibrillation. Studies monitored outcomes such as the occurrence of Ischemic Stroke and other systemic embolic events across various patient cohorts.

Research Structure for Mechanical Heart Valve Prophylaxis

Within this domain, studies research examined the VKA class in adults who have received Prosthetic Mechanical Heart Valve devices. The evidence structure for this specific population was observed in studies, reflecting the conditions studied in this setting. Studies reported measurements of outcomes reflecting daily functioning or activity level.

What remains uncertain in this domain is the modern data comparing Phenindione specifically against other VKAs for systemic embolism. Also, comparative research against newer anticoagulant agents is restricted in certain high-risk populations, such as those with mechanical heart valves, meaning the evidence is limited for this specific population.

Common questions about Dindevan (FAQ)

Q: What specific conditions are treated with Dindevan, according to regulatory approvals?

Official product information states that Dindevan is authorized for the prevention and treatment of venous thromboembolism (blood clots in veins or lungs). It is also used for prophylaxis—meaning prevention—of systemic embolisation in patients with atrial fibrillation or following the installation of a prosthetic heart valve.

---

Q: Is Dindevan used to prevent blood clots from forming after major surgery?

Yes, official documentation confirms that Dindevan is used for the prophylaxis (prevention) and treatment of venous thromboembolism. This includes contexts where there is a risk of clot formation, such as after certain surgical procedures.

---

Q: How long does it take for Dindevan to begin working after the first dose?

The full anti-coagulation effect of Dindevan is delayed because its mechanism relies on stopping the synthesis of new blood clotting factors. Since it takes time for the existing, active clotting factors to clear from the blood, the full therapeutic effect does not begin immediately after the first dose.

---

Q: What are the most common side effects reported with Dindevan use?

As with all medicines in this class, the most frequent adverse effect reported is haemorrhage (bleeding). This is an expected risk that is managed through close monitoring, as the drug's primary function is to reduce the blood’s clotting ability.

---

Q: Is a skin rash or other allergic reaction a known side effect of Dindevan?

Yes, the regulatory information lists hypersensitivity reactions, including skin rashes and urticaria (hives), as known undesirable effects. Official documents highlight the importance of recognizing the signs of these reactions.

---

Q: Can Dindevan cause liver function changes that need to be checked regularly?

The Summary of Product Characteristics recommends that the International Normalized Ratio (INR) be monitored more frequently in patients who have pre-existing liver disease. This frequent monitoring helps ensure that the dose remains appropriate and minimizes potential risks.

---

Q: Are there any known long-term health risks described for Dindevan use over several years?

The regulatory documents note that continuous, careful monitoring is necessary to manage the risk of serious but rare adverse effects. These potential effects include conditions like calciphylaxis and renal damage, which are managed through strict adherence to testing schedules.

---

Q: Do common over-the-counter pain relievers interfere with Dindevan?

Yes, regulatory documents describe interactions between Dindevan and certain common non-prescription pain relievers. Specific medicines, including aspirin, ibuprofen, and paracetamol, are listed as having known interactions.

---

Q: Can patients with pre-existing kidney or liver problems use Dindevan?

The use of Dindevan is contraindicated in severe cases of kidney or liver disease. For patients with less severe forms of these conditions, the official product information indicates the need for special caution and more frequent monitoring of the INR.

---

Q: Can Dindevan affect cholesterol-lowering medicines?

Regulatory information indicates that Dindevan has known interactions with certain medicines used to manage cholesterol. Specific agents, such as clofibrate, are listed as potentially affecting the activity of Dindevan.

---

Q: Does Dindevan dissolve blood clots that have already formed?

No, Dindevan is an anticoagulant, and its action is to prevent new blood clots from forming or existing clots from growing larger. According to the stated mechanism of action, the medicine has no direct effect on established blood clots themselves.

---

Q: How long does Dindevan remain effective in the body after the last dose is taken?

The drug's anti-coagulation effect can be prolonged, meaning that a significant effect may remain for several days after the last dose has been taken. This is due to the time required for the body to naturally clear the affected clotting factors.

---

Q: Are there any reported effects of Dindevan on hair loss or sense of taste?

Yes, regulatory listings of undesirable effects include both alopecia (hair loss) and dysgeusia (changes to the sense of taste) as reported findings.

---

Q: What symptoms indicate a serious adverse reaction to Dindevan that requires immediate attention?

Signs of excessive anti-coagulation and bleeding require immediate medical attention. These symptoms can include unusual bruising, blood in the urine, or black-colored stools.

---

Q: Are there any known interactions between Dindevan and hormonal contraceptives?

Yes, the official product documentation lists oral contraceptives as drugs that may potentiate, or increase the effect of, Dindevan.

---

Q: Are there specific periods of illness (like vomiting or diarrhea) that can affect Dindevan's action?

Yes, acute illnesses, especially those involving being sick (vomiting) or having diarrhoea, can affect the drug's activity. During these periods, official warnings note that treatment may require careful monitoring.

---

Q: Is it necessary to inform a dentist or surgeon that I am taking Dindevan before a procedure?

Official documents indicate the importance of informing the healthcare team about Dindevan use before any surgery or dental procedure. The prescribing doctor may need to adjust the dose or temporarily stop the treatment to manage the risk of bleeding.

---

Q: What is the half-life of Dindevan?

Pharmacokinetic data indicates that the half-life of the active drug substance is generally reported to be between 5 to 10 hours.

---

Q: Are there known risks associated with suddenly stopping Dindevan treatment?

Official safety principles indicate that treatment cessation should occur only under the supervision of a doctor. Unsupervised discontinuation carries the risk of negating the protective anti-coagulation effect, which may increase the underlying risk of clot formation.

---

Q: What happens if I miss a scheduled dose of Dindevan?

Due to the individualized nature of anticoagulant therapy, guidance for a missed dose is generally obtained directly from the prescribing clinician or an anticoagulant clinic. A key safety principle is to avoid taking a double dose to make up for a missed one.

---

Q: Does Dindevan have any known effect on a person's ability to drive?

According to the official product information, Dindevan is not expected to affect a person's ability to drive or operate machinery.

How to Store and Dispose of Dindevan (Phenindione)

Official regulations define strict storage and disposal requirements for Dindevan tablets to maintain product integrity and safety.

Storage Requirements

Feature	Requirement
Temperature	Store at a temperature not exceeding 25 C
Handling/Protection	Must be kept in the original container to protect it from moisture
Child Safety	Mandatory to keep the medicine out of the sight and reach of children

---

Disposal Instructions

Any unused medicinal product or waste material containing Dindevan must be disposed of in accordance with local requirements. The product should not be disposed of in general household waste or wastewater.